| DON'T BUY | 2.650 | Chris Fernyc | Drug development. Burning up cash hand over fist. In sloppy markets you have to watch out. There's no earnings or fundamental support. Very early stages in drug development and will have to raise money, so will dilute shareholders. | 2005-04-14 | |
| WEAK BUY | 2.180 | Robert Floyd | Their particular area of expertise is getting involved with drugs that are involved with transplants that reduce rejection. Outlook for the company is quite interesting. In phase 2 and 3 trials so they still have a ways to go. Speculative. | 2005-01-07 | |
| BUY | 2.900 | Mike Weir | Has a better product than cyclosporine. This should create a great marketplace for them. With more results coming out in 2004, you should see the stock move-up quite nicely. | 2004-01-26 | |
| BUY | 2.670 | Mike Weir | Thinks the stock should move up from this level. Have a good opportunity to bring their product to market. Should rally by the middle of 2004. | 2003-12-22 | |
| BUY | 3.630 | Peter Hodson | Solid growth company. Well along in clinical trials. Well run and the upside is pretty good. Some good partnerships. Good product. If you want a Cdn biotech, this is a good one. | 2003-09-09 | |
| BUY | 3.480 | Robert Floyd | An interesting little company. Good cash position. Strong management. | 2003-07-04 | |
| BUY | 3.100 | Mike Weir | Has been able to meet ,ilestones. | 2003-03-05 | |
| BUY | 4.050 | Robert Floyd | Strong joint venture. Should move up as the clinical trials go through. | 2002-07-10 | |
| BUY | 4.050 | Ray Steele | Prefers over Biomira. | 2002-01-16 | |
| TOP PICK | 4.480 | Malvin Spooner | Good product and is in phase 2. Volatile. | 2001-11-13 | |
| BUY | 4.690 | Robert Floyd | Well funded in their product line. | 2001-11-09 | |
| BUY | 3.700 | Malvin Spooner | Expects it to get some partners. | 2001-05-04 | |
Experts that have talked about Isotechnnika Inc
Rss Top Picks Feed
